熱點掃描 | 商湯上市至今漲超130%
uSMART盈立智投1月4日消息,截止發稿,港股三大指數漲跌互現,恆生指數下跌0.29%,報23206.79點,成交額496.77億;恆生科技指下跌1.08%,報5579.55點,成交額75.66億;紅籌指數上漲0.40%報3938.64點,成交額26.04億。
板塊方面,漲幅較大的板塊有賭場及博彩板塊,房地產開發板塊,其中:美高梅中國漲4.06%、新濠國際漲2.32%、銀河娛樂漲2.10%;世茂集團漲10.53%、融創中國漲5.85%。
生物技術板塊跌幅較大,其中,君實生物跌幅居前,下跌11.31%、騰盛博藥跌9.95%、康希諾生物跌8.65%、藥明生物跌7.57%。
熱門股:
商湯科技上市一週,漲幅達136%,今日盤中漲近25%,最高價達9.7港元,現漲16.77%;
同爲電動工具製造商的創科實業和泉峯控股集團都有不小的跌幅,分別跌3.11%和3.03%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.